Patrick Lin - 06 Apr 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Business - Strategy Off
Signature: /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 06 Apr 2022
Net transactions value: +$6,587
Form type: 4
Filing time: 08 Apr 2022, 16:49:49 UTC
Previous filing: 11 Apr 2022
Next filing: 19 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Purchase	$3,752	+1,200	+0.28%	$3.13	430,590	06 Apr 2022	Direct	F1
transaction	PCSA	Common Stock	Purchase	$2,835	+800	+0.19%	$3.54	431,390	07 Apr 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.18, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.45 to $3.60, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.18, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.45 to $3.60, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.